Wedbush Lowers Generation Bio Price Target to $5.50
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Wedbush lowered the firm's price target on Generation Bio (GBIO) to $5.50 from $7 and keeps a Neutral rating on the shares. Xoma (XOMA) will acquire Generation Bio for $4.2913/share plus a non-transferable CVR, with an expected close in February 2026. The firm expects the transaction to proceed and does not anticipate other bidders. The CVR will include cash at closing in excess of $28.97M, 90%-100% of savings on Generation Bio's office lease obligations, a share of milestone and royalty payments from Moderna (MRNA), and a share of payments from out-license or sale of the ctLNP delivery platform.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on GBIO
Wall Street analysts forecast GBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GBIO is 5.25 USD with a low forecast of 5.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 5.580
Low
5.00
Averages
5.25
High
5.50
Current: 5.580
Low
5.00
Averages
5.25
High
5.50
About GBIO
Generation Bio Inc., formerly Generation Bio Co., is a biotechnology company. The Company is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. It focuses on targets in T cells that are undruggable or poorly drugged. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh Investigates Shareholder Rights Violations at Diamond Hill, Generation Bio, and Contango
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Diamond Hill Investment Group, Inc. (NASDAQ:DHIL) for potential fiduciary duty breaches related to its sale to First Eagle Investments at $175.00 per share, raising concerns for shareholders.
- Potential Compensation Rights: Generation Bio Co. (NASDAQ:GBIO) is selling to XOMA Royalty Corporation for $4.2913 per share, including a non-transferable contingent value right, with Halper Sadeh assessing shareholder rights for potential payments under specific conditions.
- Merger Transaction Review: Contango ORE, Inc. (NYSE American: CTGO) is merging with Dolly Varden Silver Corporation, resulting in Contango shareholders owning approximately 50% of the combined entity, prompting Halper Sadeh to seek increased consideration for shareholders.
- Legal Consultation Services: Halper Sadeh LLC offers free legal consultations to help shareholders understand their rights and options, with no upfront legal fees required, aiming to advocate for the rights of affected shareholders.

Continue Reading
Halper Sadeh Investigates Contango ORE Merger with Dolly Varden Silver Corporation
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Contango ORE, Inc. and Dolly Varden Silver Corporation, where Contango shareholders are expected to own approximately 50% of the combined entity, potentially impacting shareholder rights.
- Legal Rights: Generation Bio Co. shareholders are being scrutinized due to the sale to XOMA Royalty Corporation at $4.2913 per share, which includes a non-transferable contingent value right that may yield additional payments, necessitating awareness of their legal rights.
- Shareholder Protection: Coeur Mining, Inc.'s merger with New Gold Inc. will result in Coeur shareholders owning about 62% of the combined company, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Legal Services: Halper Sadeh LLC offers legal services on a contingency fee basis, encouraging shareholders to consult for free to understand their legal rights and options, aiming to protect investor interests and pursue potential compensation.

Continue Reading








